hitt on tour
health & around thoughts, on the fly & on the flight
Dr. Solà-Morales has been selected to become one of the professors that will teach in this postgraduate study provided by the IQS (Instituto Químico de Sarrià).
Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective.
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.
Taking part in the XXXVII Jornadas de economia de la salud.
Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions.
Dr. Solà-Morales Serra has participated in the formulation of a new study that explains the innovative approach of drug’s public procurement.